Study on the clinical benefits of achieving serum uric acid levels below 6.0 mg/dL: A Database Approach

Study on the clinical benefits of achieving serum uric acid levels below 6.0 mg/dL: A Database Approach - Study on the clinical benefits of achieving serum uric acid levels below 6.0 mg/dL: A Database Approach

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057910

Enrollment

107600

Registered

2025-05-19

Start date

2025-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout, hyperuricemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Database registration within the database period. 2. Subjects whose serum uric acid levels are available at least once during the observation period and whose uric acid values are 8.0 mg/dL or higher at any point. The date when the serum uric acid level first exceeds 8.0 mg/dL is defined as the index date. 3. Participants whose eGFR values are available on the index date and at 365 days, plus or minus 180 days following the index date. 4. Subjects whose serum uric acid levels have been recorded on the same day as 365 days, plus or minus 180 days after the index date, as specified in inclusion criteria 3. The date closest to 365 days after the index date is defined as the follow-up date. If multiple dates are applicable, the most recent one will be chosen as the follow-up date. 5. Subjects over the age of 18 on the index date. 6. Subjects who have consecutively registered in the health insurance claims database for at least 12 months before the index month and for 24 months after the follow up date.

Exclusion criteria

Exclusion criteria: 1. Subjects who were prescribed uric acid-lowering agents from the month before the index date to the month that is 12 months prior to the index date. 2. Subjects who have been diagnosed with gout or hyperuricemia from the month before the index date to the month that is 12 months prior to the index date. 3. Subjects who have been diagnosed with cancer from the month before the index date to the month that is 12 months prior to the index date. 4. Subjects whose serum uric acid values are 50 mg/dL or higher on the index date.

Design outcomes

Primary

Measure	Time frame
1. eGFR Slope 2. Changes in clinical laboratory data 3. Incidence rates of events	—

Countries

Japan

Contacts

Public ContactTatsuya Kinjo

MOCHIDA PHARMACEUTICAL CO., LTD. MEDICAL AFFAIRS

tatsuya.kinjo@mochida.co.jp03-3225-5138

Outcome results